ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Journal of Medical Imaging and Radiation Oncology, published by WILEY, is a pivotal resource in the fields of oncology and medical imaging. With an impact factor reflective of its commitment to advancing research, the journal has maintained a robust reputation since its inception in 2008 and continues to thrive through 2024. It is indexed with an insightful ranking, with a Q2 classification in Radiology, Nuclear Medicine and Imaging, affirming its importance in these disciplines. This journal not only serves as an open access platform, allowing extensive reach and accessibility, but also fosters a scholarly community dedicated to the innovation of imaging techniques and radiation oncology practices. As a key player in disseminating crucial findings and advancements, it appeals to researchers, clinicians, and students who aim to contribute to the evolving landscape of medical imaging and cancer treatment methodologies. The journal is based in Australia, at 111 River St, Hoboken, NJ, and invites submissions that push the boundaries of current knowledge in this critical area of healthcare.

DIAGNOSTIC CYTOPATHOLOGY is a scholarly journal dedicated to advancing the field of cytopathology through the publication of high-quality research and reviews. Founded in 1985 and published by Wiley, this journal provides vital insights into the diagnosis and management of diseases through cytological techniques. With a strong presence in the academic community, it currently holds a Q3 ranking in the fields of Histology, Medicine (miscellaneous), and Pathology and Forensic Medicine, reflecting its commitment to fostering knowledge and innovation in these areas. Researchers and clinicians alike can benefit from its comprehensive articles that delve into cutting-edge methodologies and diagnostic strategies. Although not an Open Access journal, DIAGNOSTIC CYTOPATHOLOGY remains a crucial resource for professionals seeking to enhance their understanding and practice in the diagnostic realm. With an ISSN of 8755-1039 and an E-ISSN of 1097-0339, the journal continues to publish impactful studies well into 2024, ensuring that essential advancements in cytopathology reach a global audience.

CytoJournal is a leading open-access journal focused on the fields of pathology and forensic medicine, published by SCIENTIFIC SCHOLAR LLC. With its esteemed reputation, the journal has achieved a Q2 ranking in the 2023 Category Quartiles in its field, indicating its significant contribution and impact among its peers. Over its convergence from 2004 to 2024, CytoJournal has established itself as a pivotal platform for researchers, professionals, and students to disseminate and exchange pioneering research findings related to cytopathology and diagnostic techniques. With an emerging Scopus rank of #115 out of 208 in the field, the journal maintains a solid percentile ranking of 44th, underlining its importance in the scientific community. CytoJournal's commitment to facilitating open access ensures that critical insights and advancements in pathology and forensic medicine are easily accessible to those at the forefront of this essential area of study.

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

BREAST CANCER RESEARCH, published by BMC, is a prestigious open-access journal dedicated to advancing the field of oncology with a specific focus on breast cancer. Since its inception in 1999, the journal has established itself as a leading platform for disseminating high-quality research, with an impressive impact factor and recognition in the Q1 category for both Cancer Research and Oncology as of 2023. The journal is ranked 45th out of 404 in the field of Medicine _ Oncology and 37th out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, placing it in the top echelons of research quality and relevance at 88th and 84th percentiles, respectively. BREAST CANCER RESEARCH is committed to facilitating rapid and open access to groundbreaking findings, making it an invaluable resource for researchers, healthcare professionals, and students striving to enhance their understanding of breast cancer mechanisms, treatments, and prevention strategies. With its base in the United Kingdom, the journal continues to foster international collaborations and discussions aimed at improving patient outcomes and enriching cancer research worldwide.

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

CYTOPATHOLOGY is a pivotal journal published by WILEY, focusing on the dynamic field of cytopathology within the broader medical and pathological sciences. Founded in 1990, this journal has become a crucial resource for researchers, professionals, and students interested in the microscopic examination of cell samples for diagnostic purposes. With an ISSN of 0956-5507 and E-ISSN of 1365-2303, CYTOPATHOLOGY is indexed in Scopus, where it currently holds a rank of #113 in Pathology and Forensic Medicine and #43 in Histology, placing it in the Q3 quartile for multiple categories in 2023. The journal publishes original research, reviews, and clinical studies that advance the understanding and application of cytopathology and its significance in health care. Although not an Open Access journal, its commitment to providing high-quality research makes it an essential platform for disseminating knowledge in the field. Researchers and practitioners looking to stay at the forefront of cytopathology developments will find CYTOPATHOLOGY to be an invaluable resource.

ACTA CYTOLOGICA is a premier journal dedicated to the field of cytology, offering a platform for researchers, professionals, and students interested in the intricate study of cellular biology and its applications in the medical domain. Published by KARGER in Switzerland, the journal has been a vital resource since its inception in 1960 and is recognized for its rigorous peer-reviewed articles. With a notable impact factor reflecting its significance—ranked in the Q2 category in both Medicine (miscellaneous) and Pathology and Forensic Medicine, and Q3 in Histology for 2023—ACTA CYTOLOGICA continues to contribute valuable insights into cytological research and its implications for clinical practice. The journal maintains an annual focus on cutting-edge studies and reviews that enhance understanding and methodological advancements in cytology. Although it does not provide open access, it remains an essential read for those involved in histology and pathology, promising to keep them abreast of the latest findings and technological innovations in the field.